Day: August 21, 2025

On Monday, 25 August, Kaldalón hf. will auction six-month bills in a new series, KALD 26 0302 bills. The auction is held in line with the company’s policy to be a regular issuer of bills and bonds. The auction will be conducted using the Dutch method, i.e. all accepted bids will be sold to investors at the highest accepted flat yield. The bills will be issued in nominal value units of ISK 20 million. The company reserves the right to accept all bids, reject all bids, or accept bids in part. The results of the auction and allocation to investors will be announced no later than prior to market opening on Tuesday, 26 August. Landsbankinn hf. will manage the auction. Bids, stating nominal amount and flat yield, must be submitted to Landsbankinn hf. no later than 16:00 on Monday, 25 August, at the email address: verdbrefamidlun@landsbankinn.is.Payment...

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD)Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMDREYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission...

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD)Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMDREYKJAVIK, Iceland and LONDON, Aug. 21, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European...

Vow ASA (OSE: VOW) will release its report for the second quarter and first half year 2025 on Thursday 28 August 2025. The update will be published on https://newsweb.oslobors.no/ and on the company’s web site www.vowasa.com. Vow ASA is pleased to invite shareholders, investors, analysts, and other interested parties to a presentation of the results and a Q&A at 09:00 CET on the same day. Personal attendance is welcomed at Haakon VII’s gate 2, 0161 Oslo. The session will also be streamed via webcast. To register and follow the presentation online, please copy and paste the following link into your browser, click Attend and register your e-mail: https://channel.royalcast.com/landingpage/hegnarmedia/20250828_3/ For further information, please contact: Gunnar Pedersen, CEO, Vow ASA Tel: +47 91 63 03 04 Email: gunnar.pedersen@vowasa.com Cecilie...

Northern Horizon Capital AS, the management company of Baltic Horizon Fund, hereby notifies that management company’s current sole shareholder Northern Horizon A/S (registered in Denmark under register number 27599397) has signed a contract to sell all its 12,500 shares in Northern Horizon Capital AS. Under the contract concluded on 19 August 2025, the ownership of Northern Horizon Capital AS, the management company of Baltic Horizon Fund (“BHF“), is to transfer to the partners of a private investment company Grinvest, which through its Estonian subsidiary is currently also the largest investor in BHF. Grinvest is owned by three Lithuanian nationals – Antanas Anskaitis, Antanas Danys and Tomas Milašauskas. Antanas Anskaitis will acquire 4,168 shares, Antanas Danys will acquire 4,166 shares and Tomas Milašauskas will acquire...

Northern Horizon Capital AS, the management company of Baltic Horizon Fund, hereby notifies that management company’s current sole shareholder Northern Horizon A/S (registered in Denmark under register number 27599397) has signed a contract to sell all its 12,500 shares in Northern Horizon Capital AS. Under the contract concluded on 19 August 2025, the ownership of Northern Horizon Capital AS, the management company of Baltic Horizon Fund (“BHF“), is to transfer to the partners of a private investment company Grinvest, which through its Estonian subsidiary is currently also the largest investor in BHF. Grinvest is owned by three Lithuanian nationals – Antanas Anskaitis, Antanas Danys and Tomas Milašauskas. Antanas Anskaitis will acquire 4,168 shares, Antanas Danys will acquire 4,166 shares and Tomas Milašauskas will acquire...